Navigation Links
TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
Date:5/12/2008

PHILADELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperative Group (SOLTI), today announced the start of a global Phase III study that will examine the role of TYKERB(R) in the treatment of early breast cancer. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) will evaluate and compare the rate at which cancer cells disappear in the breast following treatment with TYKERB and/or trastuzumab before surgery in women with early-stage HER2-positive breast cancer. This type of treatment is referred to as neo-adjuvant therapy. TYKERB is an investigational drug and has not yet been approved for this indication.

"The evolution seen in breast cancer care has been tremendous in the last few decades," said Dr. Jose Baselga, Co-Chair on Neo-ALTTO and Chair of the SOLTI Group, Spain. "Surgery, in the form of a radical mastectomy of the breast, was traditionally the first line treatment offered to patients with little or no improvement in overall survival. Now we have a range of sophisticated targeted treatments that can significantly delay disease progression and increase survival. Through trials such as Neo-ALTTO, oncologists may be better able to optimize the use of these agents."

One in four women diagnosed with early breast cancer have tumors that are HER2-positive.(1) It is well recognized that these women have a higher risk of their cancer returning - either at the location of the original tumor or when the cancer spreads to other organs - even after receiving additional therapies.(1)

"The launch of Neo-ALTTO is extremely exciting as this study will help physicians answer important clinical questions relating to the neoadjuvant treatment regimen of HER2-positive breast cancer," said Dr. Martine Piccart, Chairperson of the Breast
'/>"/>

SOURCE GlaxoSmithKline; Breast International Group; SpanishBreast Cancer
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
2. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
3. Hospital Launches Landmark Emergency Medicine Project
4. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
5. Viatronix V3D-Colon Utilized in Another Landmark Study
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
8. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
9. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
10. Gene Therapy Provides Vision to People who Were Nearly Blind
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
(Date:6/19/2013)... ZIONA, Israel , June 19, ... that results from a phase I study in volunteers, ... advanced Parkinson,s patients, of ND0612, were presented at the ... ND0612 is a proprietary levodopa/carbidopa liquid drug formula under ... patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... AZ (PRWEB) June 19, 2013 Guests at ... healthy, wealthy and wise even if they don’t go to ... does require some early thought. , Crafty ... when they take advantage of the pet-friendly Scottsdale Paradise Valley ... Package . With at least 14 days advance notice, guests ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... Amerinet, Inc, a leading national ... to help Pacific Medical Centers implement a comprehensive ... than 17 percent over the organization’s previous clinical ... economies of scale and process standardization are two ... multi-site providers,” said Shawn Padilla, director of supply ...
(Date:6/19/2013)... lateral sclerosis (ALS), also known as Lou Gehrig,s Disease, ... classified into four distinct stages, report pathologists with the ... in the Annals of Neurology . This post-mortem ... for the first time, how the fatal degenerative disease ... nervous system to other regions of brain and spinal ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2
... is a Wholly Owned Subsidiary of Shamir, KIBBUTZ ... SHMR ) ("Shamir"), a leading provider of innovative,products ... it has,signed an agreement yesterday, June 30, 2008, pursuant ... ("Altra") from its minority,shareholder. Prior to this transaction, Shamir ...
... Conn., July 1 UTC Power, a United,Technologies Corp. ... supply St.,Helena Hospital in California,s Napa Valley with its ... will be in full,production in the summer of 2009., ... hospital and,part of Adventist Health, a not-for-profit health care ...
... July 1 Opus Healthcare Solutions, Inc.,a ... has named Ray,Bechtold, CPA, as controller. Based ... responsible for overseeing all accounting and financial,administrative ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080325/LATU040LOGO ), Bechtold joined ...
... RGEN ) announced today that Dr. Alfred L. ... Dr. Goldberg is currently a Professor of,Cell Biology at ... in,particular for elucidating the structure and function of the ... destroyed in,cells. In addition, he has made major contributions ...
... pain. This was the result of the analysis ... her colleagues and published in the current edition ... Int, 2008; 105[24]: 441-8). , http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=60552 ... more than 8000 private persons in the course ...
... staying asleep increase as women go through menopause ... Waking up earlier than planned also increases through ... The study is published in the July 1 ... "Sleep difficulties, especially problems staying asleep, are relatively ...
Cached Medicine News:Health News:Shamir Optical Industry Purchases Remaining 49% of Altra Trading GmbH 2Health News:Shamir Optical Industry Purchases Remaining 49% of Altra Trading GmbH 3Health News:St. Helena's Hospital Orders New Model 400kW Fuel Cell From UTC Power 2Health News:Opus Healthcare Solutions Names Ray Bechtold as Controller 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Sleep problems associated with menopause vary among ethnic groups 2
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... designed for rigid skeletal fixation, ... freedom in positioning the fixation ... fixation is designed for the ... positions. Craniotomies can be performed ...
Medicine Products: